The tenth batch of Pharmaceutical centralized procurement in the mainland is about to begin bidding, with 62 types of Pharmaceuticals included in the national procurement.

The national Pharmaceutical procurement declaration information public conference will be held today (12th) in Shanghai, signaling the upcoming opening of bids for the tenth national Pharmaceutical concentrated procurement. This national procurement includes 62 types of Pharmaceuticals. Since the pilot for concentrated Pharmaceutical procurement launched in 2018 in four direct-controlled municipalities and seven sub-provincial cities, the process has gradually normalized. In recent years, it has generally occurred twice a year, while the tenth batch of procurement is the only national procurement for 2024. This national procurement includes 62 types of Pharmaceuticals, covering various disease areas such as cardiovascular and cerebrovascular, digestive, tumors, and metabolism, with more than half being injections sold through Hospital channels. The procurement cycle for each variety is determined by the selection results.

AASTOCKSDec 12 10:32

John Lee Ka-chiu: The long-term goal is to establish the Hong Kong Drug Administration to jointly leverage the advantages of clinical trials with the Mainland.

During an interview with RTHK, Chief Executive John Lee Ka-chiu stated that the long-term goal of the authorities is to have its own drug regulatory agency that can approve medicines and medical devices. To achieve this goal, it is necessary to establish an office to prepare, including the need to join international organizations and strengthen clinical research. John Lee mentioned that Hong Kong and the mainland can jointly leverage advantages in clinical trials, including utilizing mainland data, such as patient databases from the 1.4 billion population or nearly 80 million people in the Greater Bay Area. When top-tier clinical trials can be conducted, pharmaceutical companies can be attracted to Hong Kong, increasing the city's competitiveness and business opportunities.

AASTOCKSDec 11 09:34

Shanghai: Accelerate the merger of csi all share investment banking & and establish a 10 billion yuan biomedical industry merger fund.

Shanghai issued the "Action Plan for Supporting Listed Companies in Mergers and Acquisitions (2025-2027)" which proposes to accelerate the merger of csi all share investment banking & and create a first-class investment bank. It will guide investment banks to form comprehensive service teams for mergers and acquisitions, and regularly organize training for intermediaries such as investment banks, accounting firms, law firms, and institutions that conduct asset evaluations to enhance their industry control capabilities and professional services for mergers and acquisitions. The action plan also suggests making good use of the foreign direct investment (ODI) filing mechanism for key areas' cross-border merger projects to facilitate listed companies acquiring high-quality overseas assets. Introducing market-oriented merger funds for professional tracks.

AASTOCKSDec 10 15:33

Express News | Shanghai aims to nurture around 10 internationally competitive listed companies in key industries such as integrated circuits, biomedical, and new materials by 2027, forming a merger and acquisition trade scale of 300 billion yuan.

BreakingsDec 10 15:15

Guosen's 2025 strategy for csi sws health care index: Innovation leads to industrial upgrade.

Current domestic medical demand continues to upgrade, the macro economy is expected to gradually warm up, and under geopolitical disturbances, the country is likely to increase support for self-controllable initiatives.

Zhitong FinanceDec 9 14:47

Hong Kong stock market afternoon review | All three indices declined, while biomedical, apple supplier, and aviation/airlines industry rose against the trend, with wuxi apptec and wuxi bio both increasing over 8%, air china limited rising over 7%, and BYD

Network technology stocks performed poorly, with Kuaishou-W down 3.05%, NetEase-S up 2.53%; multiple Hong Kong retail stocks declined, Prada dropped 3.03%, Bonjour Holdings rose 2.27%; biotechnology stocks generally rose, Wuxi Apptec rose 8.24%, Wuxi Bio rose 8.07%;

Futu NewsDec 9 12:10